Detail akcie Novartis AG Depository Receipt online

Business Summary: Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, GENOMED SA revenues increased 2% to PLN23M. Net income increased 20% to PLN1.1M. Revenues reflect Sale of Products increase of 2% to PLN22.4M, Sale of Goods and Materials increase of 15% to PLN592K. Net income benefited from Other Financial Expense decrease of 82% to PLN34K (expense), Other Operating Expense decrease of 9% to PLN504K (expense), Other Income increase of 56% to PLN86K (income).